Imaging Modality and Outcomes in Patients with Skull Base Osteomyelitis

Introduction: Skull base osteomyelitis (SBO) secondary to otitis externa is a rare but highly morbid disease, and early diagnosis and treatment is important for improving outcomes. We investigated current practices in diagnostic imaging for SBO and treatment outcomes, along with other patient characteristics that may affect outcomes.

Methods: This retrospective cohort study identified all patients at our institution diagnosed with SBO from 01/01/2007 to 12/31/2022. The following data were collected for each patient: imaging modality and results, specialty requesting the imaging, diabetes and immunocompromise status, facial nerve involvement, and culture results. Outcome was defined as treatment duration > 8 weeks required. Fisher’s exact test was used for analysis.

Results: We identified 35 patients with SBO. Initial diagnosis was made with CT in 13/35 cases, MRI in 2/35 cases, CT and MRI in 9/35 cases, and a combination of CT, MRI, and/or nuclear medicine in 10/35 cases. PET was used in 2/35 cases. In 31 patients with data on treatment duration, 4/4 (100%) patients with aspergillus-positive SBO required treatment >8 weeks compared to 8/27 (29.6%) patients without aspergillus (p = 0.0157). No significant associations with treatment duration were found for imaging modality, diabetes/immunocompromise status, or facial nerve involvement.

Conclusion: Despite recent literature recommending a shift towards PET/CT or PET/MRI to diagnose SBO, this has not carried over to current practice patterns at our institution, likely due to lack of awareness and cost. Imaging modality was not associated with treatment duration. Patients with aspergillus-positive SBO tend to require longer treatment.

 

MissingLinkText

Die Autoren geben an, dass kein Interessenkonflikt besteht.

Publikationsverlauf

Artikel online veröffentlicht:
05. Februar 2024